Evolve BioSystems is dedicated to developing the next generation of products to establish, restore, and maintain a healthy newborn gut microbiome.
Building on a decade of expertise in the partnership between the infant gut microbiome and human breast milk, Evolve is solving newborn gut dysbiosis, or an imbalance of beneficial bacteria, through microbiome-based interventions in both human and animal health.
Evolve BioSystems, Inc. has appointed Timothy B. Brown as CEO, effective August 1, 2017, while Dr. David J. Kyle, the Company's current CEO, will assume the new role of Executive Chairman of the Board and active Chief Scientific Officer.
Evolve BioSystems is proud to participate in Hambletonian Festival Week, taking place August 3rd-5th at Meadowlands Racetrack, E. Rutherford, New Jersey.
Evivo is the Only Probiotic Clinically Proven to Restore Baby’s Gut Microbiome
Evolve BioSystems, Inc. announces the introduction of Evivo, the first and only probiotic clinically proven to restore a baby’s gut microbiome to its original, natural state. Once-daily Evivo helps develop a healthy immune system and metabolism to set up babies for healthier lives.
Evolve BioSystems announced today that it has completed a $20 million Series B financing to fund the commercialization of its initial infant health products.
Come join Evolve as we enjoy the Devon Horse Show, and to learn how our animal health product, GlycoGuard® supports a healthy gut microbiome in nursing foals.
The Veterinary Innovation Summit, an event co-hosted by Texas A&M University and the North American Veterinary Community (NVAC), is a collision of different ideas, technologies, organizations, and people all committed to advancing the future of the veterinary profession.
The NEC Symposium: A Transdisciplinary Approach to Improved Outcomes, will be cohosted by the NEC Society and UC Davis, and is the first national conference to bring together leading clinicians, researchers, parent advocates and others involved in the study of neonatal NEC.